ALLMedicine™ Sickle Cell Anemia Center

Mar 25th, 2023 - Youths with sickle cell anemia (SCA) are at risk of pain crises, stroke, and early death. Complications can be reduced by the oral disease-modifying medication hydroxyurea, and in 2014, the National Heart, Lung, and Blood Institute published revis...

Mar 24th, 2023 - Even after endorsement in updated guidelines, hydroxyurea is substantially underused in youth with sickle cell anemia (SCA), new research indicates. SCA can lead to pain crises, stroke, and early death.

Mar 23rd, 2023 - National guidelines recommend that children with sickle cell anemia receive annual transcranial Doppler (TCD) screening to assess stroke risk. Our objectives were to estimate the rate of TCD screening among privately insured children with sickle c...

Mar 18th, 2023 - Sickle cell anemia (SCA) is a life-threatening genetic condition contributing to high-risk pregnancies affecting both the mother and fetus. With improved management of children with SCA, this life-threatening hematological disorder has evolved int...

Mar 17th, 2023 - Congenital anemias, including sickle cell anemia and thalassemia, are associated with cerebral tissue hypoxia and heightened stroke risks. Recent works in sickle cell disease mouse models have suggested that hyperoxia respiratory challenges can id...

Jun 19th, 2013 - This aim of this statement is to report an expert consensus on the diagnosis and treatment of cardiac dysfunction in β-thalassemia major (TM). This consensus statement does not cover other hemoglobinopathies, including thalassemia intermedia and s...

Mar 9th, 2023 - The vast majority of births with sickle cell disease (SCD) occur in Africa and 90% are thought to die before the age of five. Hydroxyurea (HU) is the only drug approved by the FDA for the treatment of sickle cell anemia. Although HU is used to tre...

Mar 8th, 2023 - This is a proof-of-concept study in adult SCA participants, ages 18 to 55 years old, to examine the safety, tolerability, and pharmacokinetic (PK), as well as the potential pharmacodynamic (PD) effects and clinical efficacy, of IMR-687 across a ra...

Mar 6th, 2023 - Sickle cell disease is a severe monogenic disorder which affects approximately 80,000 patients in the US. It is characterized by a vasculopathy with involvement of multiple organs and resulting in complications such as ischemic stroke, pulmonary h...

Feb 27th, 2023 - Social determinants of health (SDoH)-the conditions in which people are born, grow, work, live, and age-are key drivers of health and health disparities. Children with medical complexity are particularly at-risk given their high healthcare need an...

Feb 21st, 2023 - The Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) study is a multi-center, national, National Heart, Lung and Blood Institute (NHLBI)-funded grant to look at the real-world implementation of strok...

Mar 24th, 2023 - Even after endorsement in updated guidelines, hydroxyurea is substantially underused in youth with sickle cell anemia (SCA), new research indicates. SCA can lead to pain crises, stroke, and early death.

Mar 17th, 2023 - A cohort study of Medicare and Medicaid beneficiaries with sickle cell disease (SCD) showed a life expectancy of just 52.6 years, well below that of the general population. And among SCD patients, survival varied by sex and insurance status. Men, ...

Mar 16th, 2023 - Hydroxyurea (HU) is a safe, effective drug for treating sickle cell disease (SCD), first approved for this condition by the U. S.

Dec 12th, 2022 - NEW ORLEANS — A gene therapy recently made headlines for becoming the most expensive pharmaceutical ever launched — the price tag was $3.5 million for a one-off treatment with etranacogene dezaparvovec (Hemgenix) for hemophilia B. A gene therapy f...

Sep 21st, 2022 - Fewer than half of children aged 2-16 years with sickle cell anemia are receiving recommended annual screening for stroke, a common complication of the disease, according to a new Vital Signs report from the Centers for Disease Control and Prevent.